BMS-986353 / BMS  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BMS-986353 / BMS
NCT06220201: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis

Recruiting
1
98
Europe, US
CC-97540, BMS-986353, Fludarabine, Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Celgene Corporation
Multiple Sclerosis
07/27
07/27
NCT04231747: A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Completed
1
24
Canada, US
CC-97540
Juno Therapeutics, a Subsidiary of Celgene
Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL)
02/24
02/24
NCT05869955: A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases

Recruiting
1
129
Europe, US
CC-97540, BMS-986353, Fludarabine, Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Bristol-Myers Squibb Services Unlimited Company
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
11/27
11/27

Download Options